A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors

References

• Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94–101. doi:10.1038/s41586-020-1943-3
   PubMed Web of Science ®Google Scholar
• Vishwakarma M, Piddini E. Outcompeting cancer. Nat Rev Cancer. 2020;20(3):187–198. doi:10.1038/s41568-019-0231-8
   PubMed Web of Science ®Google Scholar
• Brown AJ, Chua NK, Yan N. The shape of human squalene epoxidase expands the arsenal against cancer. Nat Commun. 2019;10(1):888. doi:10.1038/s41467-019-08866-y
   PubMedGoogle Scholar
• Hausman DM. What is cancer? Perspect Biol Med. 2019;62(4):778–784. doi:10.1353/pbm.2019.0046
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1–12. doi:10.1038/s41423-019-0306-1
   PubMed Web of Science ®Google Scholar
• Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: targets, biomarkers, and remedies. Drug Resistance Updates. 2020;53:100718. doi:10.1016/j.drup.2020.100718
   PubMed Web of Science ®Google Scholar
• Tundo GR, Sbardella D, Lacal PM, Graziani G, Marini S. On the horizon: targeting next-generation immune checkpoints for cancer treatment. Chemotherapy. 2019;64(2):62–80. doi:10.1159/000500902
   PubMed Web of Science ®Google Scholar
• Affolter T, Llewellyn HP, Bartlett DW, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS One. 2019. doi:10.1371/journal.pone.0217276
   PubMedGoogle Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. doi:10.1186/s13046-019-1259-z
   PubMed Web of Science ®Google Scholar
• Toor SM, Nair VS, Decock J, Elkord E. Immune checkpoints in the tumor microenvironment. Semin Cancer Biol. 2020;65:1–12. doi:10.1016/j.semcancer.2019.06.021
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. doi:10.1073/pnas.192461099
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39. doi:10.1186/s13045-018-0582-8
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558. doi:10.1038/clpt.2008.170
   PubMed Web of Science ®Google Scholar
• Zhao L, Ren TH, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin. 2012;33(11):1339–1347. doi:10.1038/aps.2012.51
   PubMed Web of Science ®Google Scholar
• Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development. Expert Opin Drug Metab Toxicol. 2012;8(2):141–160. doi:10.1517/17425255.2012.643868
   PubMed Web of Science ®Google Scholar
• Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies. BioDrugs. 2016;30(4):275–293. doi:10.1007/s40259-016-0181-6
   PubMed Web of Science ®Google Scholar
• KEYTR UDA (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s016lbl.pdf. Accessed May 23, 2017.
   Google Scholar
• BA VENCIO (avelumab) [package insert]. Rockland, MA: EMD Serono, Inc; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf. Accessed May 23, 2017.
   Google Scholar
• IMFINZI (durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf. Accessed May 23, 2017.
   Google Scholar
• Center for Drug Evaluation and Research. TECENTRIQ Clinical pharmacology and biopharmaceutics review; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761041Orig1s000ClinPharmR.pdf. Accessed May 31, 2017.
   Google Scholar
• Baverel P, Dubois V, Jin C, et al. Population pharmacokinetics of durvalumab and fixed dosing regimens in patients with advanced solid tumors. J Clin Oncol. 2017;35(suppl):2566. doi:10.1200/JCO.2017.35.15_suppl.2566
   Google Scholar
• European Medicines Agency. Keytruda extension of indication assessment report; 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/003820/WC500212039.pdf. Accessed May 31, 2017.
   Google Scholar
• Liu C, Yu J, Li H, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101(5):657–666. doi:10.1002/cpt.656
   PubMed Web of Science ®Google Scholar
• Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol. 2014;78(1):106–117. doi:10.1111/bcp.12323
   PubMed Web of Science ®Google Scholar
• Wang E, Kang D, Bae K-S, Marshall MA, Pavlov D, Parivar K. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. J Clin Pharmacol. 2014;54(10):1108–1116. doi:10.1002/jcph.309
   PubMed Web of Science ®Google Scholar
• Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):58–66. doi:10.1002/psp4.12143
   PubMedGoogle Scholar
• Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer. 2017;5:43. doi:10.1186/s40425-017-0242-5
   PubMed Web of Science ®Google Scholar
• Libtayo. FDA drug label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761097s001lbl.pdf. Accessed 29, October 2019.
   Google Scholar
• Patel R, Bock M, Polotti CF, Elsamra S. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Expert Opin Drug Metab Toxicol. 2017;13(2):225–232. doi:10.1080/17425255.2017.1277204
   PubMed Web of Science ®Google Scholar
• Kim ES. Avelumab: first global approval. Drugs. 2017;77(8):929–937. doi:10.1007/s40265-017-0749-6
   PubMed Web of Science ®Google Scholar
• Imfinzi. FDA drug label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761069s002lbl.pdf. Accessed 29, October 2019.
   Google Scholar
• Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51(2):119–135. doi:10.2165/11596370-000000000-00000
   PubMed Web of Science ®Google Scholar
• Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol. 2014;78(1):106–117. doi:10.1111/bcp.12323
   PubMed Web of Science ®Google Scholar
• Bajaj G, Wang X, Agrawal S, et al. Model-based population pharmacokinetic analysis of nivolumab with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):58–66. doi:10.1002/psp4.12143
   PubMedGoogle Scholar
• Ahamadi M, Freshwater T, Prohn M, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):49–57. doi:10.1002/psp4.12139
   PubMedGoogle Scholar
• Desnoyer A, Broutin S, Delahousse J, et al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies. Eur J Cancer. 2020;128:119–128. doi:10.1016/j.ejca.2020.01.003
   PubMed Web of Science ®Google Scholar
• Ji H, Tang X, Dong Z, Song L, Jia YT. Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig. 2019;39(3):319–330. doi:10.1007/s40261-018-0735-0
   PubMed Web of Science ®Google Scholar
• OPDIVO (nivolumab) [package insert]. Princeton, NJ: BristolMyers Squibb Company; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s031lbl.pdf. Accessed May 23, 2017.
   Google Scholar
• Center for Drug Evaluation and Research. BA VENCIO clinical pharmacology and biopharmaceutics review; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049orig1s000clinpharmr.pdf. Accessed May 22, 2017.
   Google Scholar
• Rizvi S, Wang J, El-Khoueiry AB. Liver cancer immunity. Hepatology. 2020;73:86–103. doi:10.1002/hep.31416
   PubMed Web of Science ®Google Scholar
• YER VOY (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s074lbl.pdf. Accessed May 23, 2017.
   Google Scholar
• TECENTRIQ (atezolizumab) injection, for intravenous use[package insert]. South San Francisco, CA: Genentech, Inc; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761034s001lbl.pdf. Accessed May 23, 2017.
   Google Scholar
• US Food and Drug Administration. Guidance for Industry.Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling; 2003. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf. Accessed November 23, 2016.
   Google Scholar
• Griewing LM, Schweizer C, Schubert P, et al. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. BMC Cancer. 2021;21(1):1–10. doi:10.1186/s12885-021-08006-0
   PubMed Web of Science ®Google Scholar
• Greaves MW. Anti-inflammatory action of corticosteroids.Postgrad. Med J. 1976;52:631–633. doi:10.1136/pgmj.52.612.631
   Google Scholar
• Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–6688. doi:10.1158/1078-0432.CCR-07-0187
   PubMed Web of Science ®Google Scholar
• Harmankaya K, Erasim C, Koelblinger C, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28:1140–1144.
   PubMed Web of Science ®Google Scholar
• Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018;13(11):1771–1775. doi:10.1016/j.jtho.2018.06.004
   PubMed Web of Science ®Google Scholar
• Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–2878. doi:10.1200/JCO.2018.79.0006
   PubMed Web of Science ®Google Scholar
• Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO open. 2019;4(1):e000457.
   PubMed Web of Science ®Google Scholar
• Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. Adv Cancer Res. 2022;155:215–244. doi:10.1016/bs.acr.2022.02.006
   PubMedGoogle Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168. doi:10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Santini FC, Rizvi H, Wilkins O, et al. Safety of retreatment with immunotherapy after immunerelated toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. 2017;(suppl 35):9012. doi:10.1200/JCO.2017.35.15_suppl.9012
   Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immunerelated adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193–3198. doi:10.1200/JCO.2015.60.8448
   PubMed Web of Science ®Google Scholar
• Weber JS, Larkin JMG, Schadendorf D, et al. Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in Phase II and III trials in advanced melanoma (MEL). J Clin Oncol. 2017;(suppl 35):9523. doi:10.1200/JCO.2017.35.15_suppl.9523
   Google Scholar
• Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II andIII trials. J Clin Oncol. 2017;35:3807–3814. doi:10.1200/JCO.2017.73.2289
   PubMed Web of Science ®Google Scholar
• Boils CL, Aljadir DN, Cantafio AW. Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant. 2016;16(8):2496–2497. doi:10.1111/ajt.13786
   PubMed Web of Science ®Google Scholar
• Regalla DKR, Williams GR, Paluri RK. Immune checkpoint inhibitors in the management of malignancies in transplant recipients. Postgrad Med J. 2018;94:704–708. doi:10.1136/postgradmedj-2018-136081
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69–e71. doi:10.1200/JCO.2013.49.2314
   PubMed Web of Science ®Google Scholar
• De Bruyn P, Van Gestel D, Ost P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? Curr Opin Oncol. 2019;31(2):54–64. doi:10.1097/CCO.0000000000000505
   PubMed Web of Science ®Google Scholar
• Kean LS, Turka LA, Blazar BR. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev. 2017;276:192–212. doi:10.1111/imr.12523
   PubMed Web of Science ®Google Scholar
• Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol. 2010;11(6):535–542. doi:10.1038/ni.1877
   PubMed Web of Science ®Google Scholar
• Treanor JJ. CLINICALPRACTICE. influenza vaccination. N Engl J Med. 2016;375(13):1261–1268. doi:10.1056/NEJMcp1512870
   PubMed Web of Science ®Google Scholar
• Robin C, Beckerich F, Cordonnier C. Immunization in cancer patients: where we stand. Pharmacol Res. 2015;92:23–30. doi:10.1016/j.phrs.2014.10.002
   PubMed Web of Science ®Google Scholar
• Choi DK, Fuleihan RL, Walterhouse DO. Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer. Pediatr Blood Cancer. 2016;63(11):2011–2018. doi:10.1002/pbc.26110
   PubMed Web of Science ®Google Scholar
• Nakashima K, Aoshima M, Ohfuji S, et al. Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Hum Vaccin Immunother. 2017;13(3):543–550. doi:10.1080/21645515.2016.1246094
   PubMed Web of Science ®Google Scholar
• Waqar SN, Boehmer L, Morgensztern D, et al. Immunogenicity of influenza vaccination in patients with Cancer. Am J Clin Oncol. 2018;41(3):248–253. doi:10.1097/COC.0000000000000257
   PubMed Web of Science ®Google Scholar
• Chong CR, Park VJ, Cohen B, et al. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis. 2020;70(2):193–199. doi:10.1093/cid/ciz202
   PubMed Web of Science ®Google Scholar
• Hakim H, Allison KJ, Van de Velde LA, et al. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine. 2016;34(27):3141–3148. doi:10.1016/j.vaccine.2016.04.053
   PubMed Web of Science ®Google Scholar
• Wijn DH, Groeneveld GH, Vollaard AM, et al. Influenza vaccination in patients with lung cancer receiving anti–programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer. 2018;104:182–187. doi:10.1016/j.ejca.2018.09.012
   PubMed Web of Science ®Google Scholar
• Chong CR, Park V, Harding JJ, et al. Safety of influenza vaccination in patients undergoing immunotherapy treatment for advanced cancer. J Clin Oncol. 2018;36(15_suppl):e15073–e15073. doi:10.1200/JCO.2018.36.15_suppl.e15073
   Web of Science ®Google Scholar